查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1226725

动物用皮肤治疗药的全球市场:现状分析、预测(2022年～2028年)

Veterinary Dermatology Drugs Market: Current Analysis and Forecast (2022-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 159 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球动物用皮肤治疗药的市场规模，由于技术进步和动物用製药公司投资增加，以约9％稳定成长。还有主要企业急速投入新产品，对市场成长带来好影响。再加上养宠物的人数扩大，对宠物的更佳治疗选择的需求剧增，市场预期以惊异性的速度成长。

本报告提供全球动物用皮肤治疗药市场相关调查分析，各市场区隔、各地区的市场洞察，市场动态，市场趋势，竞争情形，企业简介等系统性资讯。

目录

第1章 市场简介

第2章 调查手法、前提条件

第3章 市场概要

第4章 摘要整理

第5章 COVID-19对动物用皮肤治疗药市场的影响

第6章 动物用皮肤治疗药市场收益(2020年～2028年)

第7章 市场洞察:各动物类型

  • 宠物
  • 家畜动物

第8章 市场洞察:各给药途径

  • 局部
  • 注射
  • 口服

第9章 市场洞察:各症状

  • 寄生虫感染疾病
  • 过敏感染疾病
  • 其他

第10章 市场洞察:各流通管道

  • 零售
  • 电子商务
  • 院内药局

第11章 市场洞察:各地区

  • 北美
    • 美国
    • 加拿大
    • 其他北美
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他地区

第12章 动物用皮肤治疗药:市场动态

  • 推动市场要素
  • 市场课题
  • 影响分析

第13章 动物用皮肤治疗药:市场机会

第14章 动物用皮肤治疗药:市场趋势

第15章 需求方面、供给侧面的分析

  • 需求面分析
  • 供给侧面分析

第16章 价值链分析

第17章 竞争模式

  • 竞争情形
    • 波特的五力分析

第18章 企业概要

  • Elanco
  • Vetoquinol
  • CEVA
  • Zoetis
  • Vivaldis
  • Bimeda, Inc.
  • Boehringer Ingelheim
  • Bayer
  • Merck KGaA
  • Mars, Incorporated

第19章 免责声明

简介目录
Product Code: UMME211612

Veterinary dermatology drugs refer to the medications which are indicated for the management of harmful, deadly skin infections, such as parasitic skin diseases, dander-related skin disorders, alopecia, intrinsic skin infections, autoimmune skin diseases, mild and harmful skin cancer, and other internal causes for skin abnormalities. The veterinary dermatology drugs market is anticipated to grow at a tremendous rate owing to the increase in the number of pet owners and the surge in demand for better treatment options for companion animals. For instance, as of 2021, 3.2 million families in the United Kingdom had added a pet since the pandemic's commencement, according to the Pet Food Manufacturers Association. With 12 million cats, 12 million dogs, 3.2 million small mammals like guinea pigs and hamsters, 3 million birds, and 1.5 million reptiles, there are currently 34 million pets in the United Kingdom.

The Veterinary Dermatology Drugs Market is expected to grow at a steady rate of around 9% owing to rise in technological advancements and an increase in investment by veterinary pharmaceutical firms. The key players are rapidly launching novel products, which are also having a positive impact on market growth. For instance, in 2022, Vetoquinol launched PHOVIA in Canada, which is an innovative system that aims to lessen the challenges of the current standard of care through the use of Fluorescent Light Energy (FLE). Although this technology is already used in human medicine, Vetoquinol is the pioneer of its use in the veterinary world.

Based on animal type, the market is segmented into companion animal and livestock animal. The companion animal held the dominant share of the market in 2020 due to a surge in the number of pet owners. According to the annual report of the European Pet Food Industry Association (FEDIAF), published in July 2022, cats and dogs are the most common companion animals in Europe, with 26% of all pet-owning households owning a cat, or 110 million household cats, and 25% owned dogs or 90 million dogs. Thus, this trend is anticipated to drive segmental growth during the forthcoming years.

On the basis of route of administration, the market is categorized into topical, injectable, and oral. The injectable category is expected to grow with high CAGR during the forecast period as it allows accessible administration in lesser number of doses in comparison to oral drugs. For instance, Convenia by Zoetis treats the animal in only one dose as compared to 28 doses of pills.

On the basis of indication, the market is segmented into parasitic infections, allergic infections, and others. The parasitic infections held a significant share of the market in 2020 due to the surge in the incidences of parasitic infections among animals. According to WebMD, a study conducted by Colorado State University in May 2021, found Lyme disease-carrying ticks, abundantly near beaches of Northern California, the U.S.

On the basis of distribution channel, the market is segmented into retail, e-commerce, and hospital pharmacies. The e-commerce segment is expected to grow with a high CAGR during the forecast period which is attributable to the rising penetration of veterinary products specific e-commerce websites and veterinary telehealth platforms. For example, in 2020, Vetster launched an innovative pet wellness platform through which pet owners can schedule appointments using voice, video, and chat that connects them to a market of qualified veterinary practitioners. Thus, these advancements is anticipated to drive segmental growth during the forecast period.

For a better understanding of the market adoption of the veterinary dermatology drugs, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. Several factors, such as rising medical & diagnostic capabilities for companion animals and increasing ownership of companion animals is expected to support the growth and demand for veterinary dermatology drugs in the region. Apart from this, Asia Pacific is home to manufacturing facilities of keys players in the market, such as Elanco, which further boosts growth.

Some of the major players operating in the market include: Elanco; Vetoquinol; CEVA; Zoetis; Vivaldis; Bimeda, Inc.; Boehringer Ingelheim; Bayer; Merck KGaA; and Mars, Incorporated.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Veterinary Dermatology Drugs Market
  • 2.2. Research Methodology of the Veterinary Dermatology Drugs Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE VETERINARY DERMATOLOGY DRUGS MARKET

6 VETERINARY DERMATOLOGY DRUGS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY ANIMAL TYPE

  • 7.1. Companion Animal
  • 7.2. Livestock Animal

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

  • 8.1. Topical
  • 8.2. Injectable
  • 8.3. Oral

9 MARKET INSIGHTS BY INDICATION

  • 9.1. Parasitic Infections
  • 9.2. Allergic Infections
  • 9.3. Others

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 10.1. Retail
  • 10.2. E-Commerce
  • 10.3. Hospital Pharmacies

11 MARKET INSIGHTS BY REGION

  • 11.1. North America
    • 11.1.1. U.S.
    • 11.1.2. Canada
    • 11.1.3. Rest of North America
  • 11.2. Europe
    • 11.2.1. Germany
    • 11.2.2. U.K.
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. Asia-Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Rest of Asia-Pacific
  • 11.4. Rest of World

12 VETERINARY DERMATOLOGY DRUGS MARKET DYNAMICS

  • 12.1. Market Drivers
  • 12.2. Market Challenges
  • 12.3. Impact Analysis

13 VETERINARY DERMATOLOGY DRUGS MARKET OPPORTUNITIES

14 VETERINARY DERMATOLOGY DRUGS MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 15.1. Demand Side Analysis
  • 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

  • 17.1. Competitive Landscape
    • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

  • 18.1. Elanco
  • 18.2. Vetoquinol
  • 18.3. CEVA
  • 18.4. Zoetis
  • 18.5. Vivaldis
  • 18.6. Bimeda, Inc.
  • 18.7. Boehringer Ingelheim
  • 18.8. Bayer
  • 18.9. Merck KGaA
  • 18.10. Mars, Incorporated

19 DISCLAIMER